

Does Antibiotic Resistance Evolve in Hospitals?

Anna Seigal¹, Portia Mira², Bernd Sturmfels¹, Miriam Barlow^{2*}

¹ Department of Mathematics, University of California, Berkeley, USA

² School of Natural Sciences, University of California, Merced, USA

Keywords: Infection control, Antibiotic Resistance, Nosocomial Outbreaks, ESBL, Markov Chain

Corresponding Author Information:

*mbarlow@ucmerced.edu

5200 North Lake Road

Merced, CA 95343

+1.209.228.4174

Key Points:

Nosocomial outbreaks and horizontal exchange of antibiotic resistance genes are serious health problems. Our method detects significant patterns of antibiotic resistance transmission. Potential uses include detection of clonal outbreaks and determining the effectiveness of antibiotic cycling efforts.

Abstract:

Nosocomial outbreaks of bacteria have been documented many times. Based on these incidents, and the heavy usage of antibiotics in hospitals, it has been assumed that antibiotic resistance evolves in hospital environments. To test this assumption, we analyzed the resistance phenotypes of bacteria collected at a community hospital over a 2.5-year period.

First, to assess dependence of antibiotic resistance on factors other than time, we performed a graphical model analysis. We found no association between resistance and other patient data (age, gender, infectious species, and sample type).

We created a mathematical method called the Nosocomial Evolution of Resistance Detector (NERD). It calculates the significance of resistance trends occurring in a hospital. It can inform hospital staff about the effects of various practices and interventions, can be used to help detect clonal outbreaks, and is available free of charge.

We applied our method to each of the 16 antibiotics in the study via 16 hypothesis tests. For 13 of the antibiotics, we found that the hospital environment had no significant effect upon the evolution of resistance; the hospital is merely a piece of the larger picture. The p-values obtained for the other 3 antibiotics (Cefepime, Ceftazidime and Gentamycin) indicate that particular care should be taken in hospital practices with these antibiotics. One of the three, Ceftazidime, was significant after accounting for multiple hypotheses, indicating a significant evolution of hospital-based resistance for this drug.

Introduction:

Antibiotic resistance is a global problem that results from evolutionary pressures imposed by antibiotic consumption on an industrial scale in agricultural, clinical, and outpatient settings. Immigration of resistant strains causes their dissemination throughout the world. However, regional differences in the first appearance of resistance mechanisms and subsequent frequencies indicate that local factors are also important. It is unclear whether global population dynamics, regional factors, or immediate proximity to antibiotics determines the frequencies of resistance phenotypes in a defined location, such as a hospital. Any insight into the greatest contributors to this problem could have major effects on public health policy.

Several efforts have attempted to reduce the frequencies of resistant isolates, with mixed success. Cycling antibiotics in patients has shown promising results [1], and decreasing consumption of aminoglycosides in hospitals tends to reduce resistance to them [2]. However, for β -lactam antibiotics, there is no clear trend of reduced resistance in response to reduced consumption.

Despite a nationwide effort to reduce β -lactam prescriptions in Turkey, β -lactam resistance increased, except for carbapenam resistance in *Pseudomonas* and *Acinetobacter*. The frequency of Methicillin Resistant *Staphylococcus aureus* (MRSA) also decreased [3].

In Denmark, an agricultural ban of growth promoting antibiotics has resulted in a significant decrease in the frequency of ampicillin, nalidixic acid, sulfonamide, tetracycline, erythromycin, and streptomycin resistant bacteria in food animals [4]. The ban also resulted in a decrease in Vancomycin Resistant Enterococci in both animal and human populations [5].

Our study addresses the potential role of hospital-based efforts. Implicit in any hospital-centered effort to reduce the prevalence of antibiotic resistance is the assumption that antibiotic resistance actually evolves in hospitals. Anecdotal evidence supports this assumption. For example, in 2011 the U.S. National Institutes of Health Clinical Center experienced an outbreak of carbapenam-resistant *K. pneumonia* that affected 18 patients, 11 of whom died [6]. This scenario illustrates that a bacterial strain from a single patient can become endemic, and likely evolve within the hospital. The inconsistent results from cycling and decreased consumption may result from many factors, including the choice of antibiotics, duration of therapies, immigration into the hospital from the surrounding community, and insensitivity of tools for assessing resistance trends.

We questioned whether bacteria in hospitals are evolving within the hospital environment, or whether their population dynamics are a function of immigration. To address this question, we conducted a case study with Dignity Health Mercy Medical Center, a small community hospital in the Central Valley of California. We developed a general method, and software package, for analyzing temporal antibiotic resistance data from patients.

Results:

Nosocomial Evolution of Resistance Detector (NERD):

We developed an automated method that incorporates a model of evolution to determine whether resistance rates are caused by the hospital environment, or bacterial populations at a larger scale. We called it the Nosocomial Evolution of Resistance Detector (NERD). It analyzes resistant trends over time for an antibiotic. It is freely available in the open-source package “NERD” of the statistics software “R”. The method produces a p-value to assess the significance of hospital-associated trends while minimizing the masking effect of infectious strains brought in by patients.

The NERD method takes as input de-identified patient data including temporal information (e.g. days since the study began) and the resistance status of the patient (e.g. resistant, intermediate, susceptible). There are two user-defined parameters, from a negative binomial distribution, whose choice enables specialization of the method to various antibiotic resistance scenarios. We collected information from published nosocomial outbreaks (Table 4) to estimate these parameters (see Methods).

We modeled resistance as a Markov Chain (Figure 1) whose states are the possible resistance statuses of patients. A Markov chain is a stochastic process in which a future state depends only on the present state, not on the history. We believe this is how antibiotic resistance evolves. The transition probability (p_{ij}) is the probability of going from state “i” to state “j”. It is an aggregated measure of an earlier patient with state “i” and a later record with state “j”, weighted by the potential for causality. This weight is a function of the delay between time stamps of the two patients.




Figure 1: Evolution of antibiotic resistance as modeled by a three-state Markov chain. Nodes represent the three states. Arrows represent transitions and are labeled by probabilities.

Table 1: The nine transition probabilities of the Markov chain.			
	Susceptible	Intermediate	Resistant
Susceptible	p_{SS}	p_{SI}	p_{SR}
Intermediate	p_{IS}	p_{II}	p_{IR}
Resistant	p_{RS}	p_{RI}	p_{RR}

Within this framework we developed a hypothesis test for evolution of antibiotic resistance in the hospital. The null hypothesis is that there is no such evolution, i.e. the transition probabilities depend only on their final state. We compare our estimated transition probabilities with those generated under the null hypothesis and record their significance as a p-value.

Data Collection:

We collected 592 multi-drug resistant (MDR) isolates between June 2013 and January 2016 along with the patient record associated with each isolate. Each of the 592 records (see SI) contains the date of isolation, gender, age, tissue, and susceptibility test results to 16 antibiotics (Table 2).

The isolate responses to each of the 16 antibiotics were organized into three possible categories: Susceptible (S), Intermediate (I) or Resistant (R). We excluded 77 records that were incomplete or unreliable. Among the 515 remaining records, most contained susceptibility testing for all 16 antibiotics.

Table 2: Summary of Susceptibility Testing Results.			
	Susceptible	Intermediate	Resistant
Ampicillin	0	0	470
Ampicillin/Sulbactam	85	113	284
Piperacillin/Tazobactam	429	46	30
Cefazolin	2	3	509
Ceftazidime	6	3	505
Ceftriaxone	6	0	508
Cefepime	7	2	505
Ertapenem	511	0	3
Imipenem	510	0	3
Amikacin	506	2	6
Gentamycin	343	2	169

Tobramycin	280	58	176
Ciprofloxacin	51	4	458
Levofloxacin	55	5	453
Nitrofurantoin	412	59	42
Trimetprim/Sulfamethoxazole	174	0	339

Graphical Model Analysis:

Before applying the NERD method, we tested the dependence of resistance on factors that could interfere with the temporal trend. Graphical modeling is a statistical tool for studying dependence structures for several random variables [7]. We incorporated six random variables with discrete states: gender (male, female) and age (in decades) of the patients, tissue of the sample (urine, blood, wound, or sputum), species of bacteria (*E. coli* or *K. pneumonia*), resistance status (S, I, R), and antibiotic (See Figure 2).




Figure 2: Best fitting graphical model. Each node is a discrete random variable. An edge between two nodes indicates statistical dependence. The first four nodes, (age, gender, tissues and species) have no edges to the last two nodes (antibiotics, R/I/S). The disconnectedness indicates statistical independence.

The analysis showed that Age, Tissue, Species and Gender are not correlated to the resistance status. We therefore disregarded those variables in the subsequent analysis and used only the date of isolation, the antibiotic and the resistance information.

Application of NERD to Our Data:

We used the NERD method to study each of the 16 antibiotics separately. The results for our hypothesis test, with mean parameter 139 and dispersion 8.8, can be seen in Table

3. We do not specifically focus on those antibiotics that have low p-values, thus, our p-values have not been corrected for multiple hypothesis testing. We found that the hospital environment did not have a significant effect on the evolution of over $\frac{3}{4}$ of the antibiotics. However, the antibiotics Ceftazidime, Cefepime and Gentamycin have p-values below 0.05. Their robust departure from randomness indicates that the hospital environment, with antibiotic prescribing as a likely cause, can influence the frequencies of antibiotic resistant bacteria. While the p-values of Cefepime and Gentamycin are not significant after Bonferroni correction, their small p-values are still interesting. Figure 3 shows the directionality of their resistance trend.

Table 3: Hypothesis test p-value results.	
Antibiotic	p-value
Ampicillin	All samples resistant
Ampicillin/Sulbactam	0.141
Piperacillin/Tazobactam	0.426
Cefazolin	0.317
Ceftazidime	0.003*
Ceftriaxone	0.659
Cefepime	0.032
Ertapenem	0.395
Imipenem	0.403
Amikacin	0.565
Gentamycin	0.020
Tobramycin	0.116
Ciprofloxacin	0.096
Levofloxacin	0.123
Nitrofurantoin	0.192
Trimethoprim/Sulfamethoxazole	0.224




Figure 3: Change in relative cumulative resistance of three antibiotics over time.

The graph plots the difference between the actual cumulative resistance, seen from our data, and the expected cumulative resistance. A value below 0 indicates an antibiotic with a trend from Susceptibility to Resistance over time; a value above 0 indicates a trend from Resistance to Susceptibility. Cefepime and Ceftazidime have a trend away from resistance. The trend for Gentamycin is neither positive nor negative overall. Its trend follows an annual cycle, indicating seasonal variations in the resistance trend.

Our study involved two species of bacteria (*E. coli* and *K. pneumonia*). To determine whether the two species yielded different results, we ran the method separately for each; this had no effect on p-values.

Discussion:

We have presented a method called “NERD” for identifying significant evolutionary trends of antibiotic resistance in hospitals. This method can be useful in the detection of clonal outbreaks, determining the effectiveness of antibiotic cycling or antibiotic restriction efforts, detecting decreases in antibiotic resistance, investigating horizontal transfer and transmission of antibiotic resistance within a hospital, and identifying nosocomial infections.

For 13 of the 16 antibiotics we studied, the hospital environment did not contribute to the evolution of antibiotic resistance more than outside factors. The histories of these antibiotics provide some context for our findings.

Ampicillin is a penicillin which is heavily used by the agricultural industry. Cephalosporins (Cefazolin and Ceftriaxone) have structural similarities with penicillins and share related resistance mechanisms. Immigration of resistant strains into the hospital likely contributes more to the frequencies of this resistance phenotype than hospital consumption of these antibiotics.

Ampicillin/Sulbactam and Piperacillin/Tazobactam are penicillin antibiotics combined with resistance inhibitors. These were introduced in the early 1980's [8]. As the world-wide resistance problem for other antibiotics has increased, so has their consumption [9]. Ampicillin/Sulbactam resistance rates are quite high in the strains we studied, but resistance to Piperacillin/Tazobactam was fairly uncommon. We suspect that resistance to this drug is still emerging. While the resistance rates we observed appear to be affected more by bacterial populations outside the hospital than within, judicious usage of these antibiotics in all possible situations may help maintain low resistance rates.

The Carbapenems (Ertapenem and Imipenem) are exceptional β -lactam antibiotics. Although they have some structural similarity with penicillins and cephalosporins, mechanisms of resistance for them are different. Resistance rates for these antibiotics are low in most hospitals and communities. For that reason, these antibiotics are often reserved as a last resort for life and death situations. Restricted consumption of these antibiotics most likely accounts for their insignificant p-values in our study.

Fluoroquinolones (Ciprofloxacin and Levofloxacin) became the most heavily used antibiotics in the USA after the 2001 anthrax attacks because Ciprofloxacin was the only antibiotic that had FDA approval for the treatment of anthrax. Since that time their popularity has persisted, and resistance to them has increased. They have shared resistance mechanisms. Broad outpatient use of Ciprofloxacin probably contributes more to resistance in bacterial populations than hospital consumption because.

Several antibiotics we analyzed have been used extensively for decades. Immigration of resistant bacteria into the hospital probably has as much effect on bacterial populations as hospital consumption of antibiotics. Aminoglycosides (Tobramycin) received FDA approval in the 1970s and some have been used heavily in agriculture. Nitrofurantoin received FDA approval in 1953. Trimethoprim/Sulfamethoxazole received FDA approval in 1973. It can be used as an outpatient drug. For these antibiotics, wide consumption and the duration of use probably limit the effect of current hospital consumption.

The hospital environment affected three of the antibiotics in our study. The evolution of Cefepime and Ceftazidime resistance as a function of the hospital environment is particularly striking. Cefepime is a cephalosporin type antibiotic that was introduced in 1994. It is only administered through injection and has no outpatient applications. Novel resistance mechanisms emerged that efficiently confer resistance to this antibiotic. One of the first efficient resistance mechanisms for Cefepime was CTX-M [10]. Numerous clinical strains of *E. coli* [11, 12] and *K. pneumonia* [13, 14] are resistant to Cefepime as a result of CTX-M expression. The frequency of CTX-M in clinical populations of bacteria has increased rapidly and is now replacing other genes as the most commonly encountered. In particular, CTX-M-15 confers resistance to both Cefepime and Ceftazidime and is commonly detected in hospitals. The similarities of Cefepime and Ceftazidime re-

sistance trends suggest that CTX-M-15 is the genetic element associated with these trends. In future studies we plan to confirm that CTX-M-15 is expressed in these isolates.

Gentamicin is an aminoglycoside, available since the 1970s. Despite heavy use in agriculture, resistance rates for this antibiotic are moderate. It is also useful in the treatment of urinary tract infections. Since the emergence of CTX-M resistance genes and Carbapenem resistant Enterobacteriaceae in urinary tract infections, non- β -lactam antibiotics have become necessary as primary treatment options for UTIs, and this may explain the significant Gentamicin resistance trend we observed.

Our results highlight that individual hospitals are important but small pieces of the overall resistance problem. Factors such as agricultural antibiotic consumption, outpatient prescriptions and a high global frequency of resistance genes also have a strong effect. Our results highlight the necessity of addressing antibiotic resistance at a larger scale. This may be at a community, regional, national, or global scale. Efforts at all levels are likely to help.

Methods:

A total of 592 samples were collected from patients of Dignity Health Mercy Medical Center in Merced, California, between June 24, 2013 and January 23, 2016. The samples were identified as Extended Spectrum β -lactamases (ESBL's) using Vitek 2 Version 06.01, an automated rapid detection system for pathogen identification and antibiotic sensitivity. The sensitivity to 16 antibiotics was also tested and the samples were categorized according to their susceptibility according to CLSI M100-S18 (2008).

For each sample, we recorded the date of isolation, the age and the gender of the patient, the species of the bacteria, the tissue/source of the isolate, and the susceptibility (R/I/S) to the following 16 antibiotics: Ampicillin, Ampicillin/Sulbactam, Piperacillin/Tazobactam, Cefazolin, Ceftazidime, Ceftriaxone, Cefepime, Ertapenem, Imipenem, Amikacin, Gentamicin, Tobramycin, Ciprofloxacin, Levofloxacin, Nitrofurantoin and Sulfamethoxazole/Trimethoprim.

Graphical Model:

We studied the dependence structure among the six discrete random variables: gender (male or female), age (by decades), tissue source of the sample (urine, blood, wound, or sputum), species of bacteria (*E. coli* or *K. pneumonia*), resistance status (S, I, or R), and antibiotic. The hospital data are recorded in a contingency table of format $2 \times 10 \times 4 \times 2 \times 3 \times 16$. We fit a graphical model to the table as in the book *Graphical Models in R* [15]. Starting from the full independence model (the graph with no edges), we compute the Akaike Information Criterion (AIC) at each stage of edge insertion. This was done using the function *forward* in the “gRim” package for the statistics software “R” [16]. This ascertains the correct balance between numbers of edges (parameters) and fit to the data. We also started the algorithm from the saturated model (the graph with all edges), and used the *backward* function to compute the AIC of successive edge deletions. Both methods gave the graph in Figure 2.

Parameter Estimation:

Rare-event interactions have a causal effect on antibiotic resistance status. We model them using the negative binomial distribution [17], a discrete probability distribution that records the number of failures before some fixed number, k , of successes. It relies on two parameters: mean (m) and over-dispersion (k). Its probability density function is

$$P(X = x) = \binom{x + k - 1}{x} p^x (1 - p)^k.$$

The parameter k measures how much the variance exceeds the mean, also known as the size of the distribution. The trials (successes or failures) represent patients at the hospital. Failure is when a patient's antibiotic resistance status is changed. Success is when it does not change. After k patients have not had their resistance status causally affected, we assume no future patients will either.

The exact values of the two parameters are not known in practice; they are estimated using the studies from the literature in Table 4. We assumed that the distributions of these deadly outbreaks are the same as the patterns of changes to antibiotic resistance status.

Table 4: Summarized information from clonal outbreaks and estimates of λ					
Outbreak strain	Size of hospital (beds)	Number of patients in outbreak	Average time from patient 0 (days)	Variance	Reference
<i>K. pneumoniae</i>	880	127	439	37856	[19]
<i>K. pneumoniae</i>	1492	93	1027	49449	[20]
<i>E.coli</i>	NA-community clinical lab	69	340.6	30336	[21]
<i>K. pneumoniae</i>	243	17	108.6	2002	[6]
<i>K. pneumoniae</i>	81	7	122	4852	[22]
<i>K. pneumoniae</i>	301	36	147	7886	[23]
<i>E. coli</i>	66 (NICU)	21	103	4036	[24]

Table 4 indicates the importance of the size of the hospital in its distribution. Dignity Health Mercy Medical Center has 186 beds. We fit our negative binomial parameters to the hospital that was most similar in size, with 243 beds. The parameter fitting was done using the function *fitdistr* in the R package “MASS” [18]. We obtained

Mean: $m = 115$

Over-dispersion: $k = 8.8$.

NERD Method:

The method estimates the transition probabilities by weighting the potential of an earlier patient's antibiotic resistance status causing that of a later patient. The weight depends on the elapsed time between the patients' visits. If the first patient visited several years ago, we assume there is no causal relationship between isolates, and likewise if the first patient's visit was a few hours ago. Under our model, the weight is given by the probability density function of our negative binomial distribution, evaluated at the elapsed time between the two records.

For each of the nine combinations (SS, SI, SR, IS, II, IR, RS, RI, RR), we sum the weighted contribution of all pairs of records with these states. This gives a 3x3 table, which we convert into estimated transition probabilities by normalizing each row to sum to one. We have an empirical transition matrix, such as the example in Table 5.

Table 5: Empirical transition probabilities for Ampicillin/Sulbactam			
	Susceptible	Intermediate	Resistant
Susceptible	0.1778246	0.2377849	0.5843905
Intermediate	0.1625636	0.2345707	0.6028657
Resistant	0.1711736	0.2280554	0.6007710

The null hypothesis assumption is that there is no trend towards antibiotic resistance. This implies that the three rows of the matrix of transition probabilities should be identical, indicating that future antibiotic resistance status is not affected by present status. Each row is the proportion of patients of each resistance status, obtained by dividing the number of S, I or R counts by the total number of patient records. Dividing the row of Table 2 corresponding to Ampicillin/Sulbactam by 85+113+284=482, we obtain Table 6.

Table 6: Expected transition probabilities for Ampicillin/Sulbactam under the null hypothesis			
	Susceptible	Intermediate	Resistant
Susceptible	0.1763485	0.2344398	0.5892116
Intermediate	0.1763485	0.2344398	0.5892116
Resistant	0.1763485	0.2344398	0.5892116

The observed values in Table 5 differ from the expected values in Table 6. To quantify this difference, we calculate the χ^2 test statistic

$$\sum_{\substack{\text{entries} \\ \text{of table}}} \frac{(\text{observed} - \text{expected})^2}{\text{expected}}.$$

Next, we use a permutation test to compare our test statistic with that of randomly generated data. In theory, the p-value is obtained by considering all possible permutations of the observed resistance information, and finding the proportion of permutations that have larger χ^2 value than our observed data. For example, for Ampicillin/Sulbactam, the total number of possible permutations is the multinomial coefficient

$$\binom{482}{85, 113, 284} = \frac{482!}{85! 113! 284!} = 6 \times 10^{197}$$

We approximated this extremely large discrete problem to good accuracy, by generating 10,000 random permutations of the data. The p-value is the proportion of permutations whose χ^2 test statistic is larger than the value from the data, see Table 3.

Relative Cumulative Resistance:

The final stage is to determine the directionality of the trend at play for those antibiotics whose Markov analysis yielded significant p-values. For this we compute the relative cumulative resistance.

The cumulative resistance at time t is the number of resistant isolates plus half the number of intermediate isolates recorded up to that time. The expected trend is a straight line between zero resistance in June 2013, and the total cumulative resistance in January 2016. A concentration of susceptible patients near the start gives a cumulative resistance curve below the expected line. More resistant patients at the start result in a cumulative resistance exceeding the expected level at the start.

The relative cumulative resistance is the observed cumulative resistance minus the expected cumulative resistance. It shows how the cumulative resistance compares with the expected linear rate (see Figure 3).

Conflict of Interest: The authors have no conflict of interest.

Acknowledgements: We thank Dignity Health Mercy Medical Center and especially Robert Salcido, Glenn Bruss and Robert Streeter for providing clinical data and strains. We thank Joe Kileel for help organizing the data and defining the final data set. We are grateful to Lior Pachter for very helpful comments on an earlier version of this paper. This study was funded by CITRIS Seed Grant #: 2015-324.

References

1. Poirier C, Dinh A, Salomon J, Grall N, Andremont A, Bernard L. Antibiotic cycling prevents urinary tract infections in spinal cord injury patients and limits the emergence of multidrug resistant organism. *J Infect* **2015**; 71(4): 491-3.
2. Brown EM, Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. *J Antimicrob Chemother* **2005**; 55(1): 6-9.
3. Altunsoy A, Aypak C, Azap A, Ergonul O, Balik I. The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey. *Int J Med Sci* **2011**; 8(4): 339-44.
4. World Health Organization. Impacts of Antimicrobial Growth Promoter Termination in Denmark. Available at: apps.who.int/iris/bitstream/10665/68357/1/WHO_CDS_CPE_ZFK_2003.1.pdf.
5. Casewell M, Friis C, Marco E, McMullin P, Phillips I. The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. *J Antimicrob Chemother* **2003**; 52(2): 159-61.
6. Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing. *Sci Transl Med* **2012**; 4(148): 148ra16.
7. Lauritzen SL. *Graphical Models*: Oxford University Press, **2004**.
8. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. *Clin Microbiol Rev* **2010**; 23(1): 160-201.
9. Belaaouaj A, Lapoumeroulie C, Canica MM, et al. Nucleotide sequences of the genes coding for the TEM-like beta-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). *FEMS Microbiol Lett* **1994**; 120(1-2): 75-80.

10. Tzouveleakis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes. *Int J Antimicrob Agents* **2000**; 14(2): 137-42.
11. Doi Y, Paterson DL, Adams-Haduch JM, et al. Reduced susceptibility to cefepime among *Escherichia coli* clinical isolates producing novel variants of CMY-2 beta-lactamase. *Antimicrob Agents Chemother* **2009**; 53(7): 3159-61.
12. Mansouri M, Ramazanzadeh R, Norabadi P. Cefepime resistance and associated risk factors among *Escherichia coli* strains isolated from clinical specimens. *Chemotherapy* **2011**; 57(2): 134-7.
13. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against *Escherichia coli* and *Klebsiella pneumoniae* strains producing extended-spectrum beta-lactamases: report from the ARREST program. *Antimicrob Agents Chemother* **2003**; 47(5): 1643-6.
14. Wang P, Hu F, Xiong Z, et al. Susceptibility of extended-spectrum-beta-lactamase-producing *Enterobacteriaceae* according to the new CLSI breakpoints. *J Clin Microbiol* **2011**; 49(9): 3127-31.
15. Højsgaard S, Edwards D, Lauritzen SL. *Graphical Models with R*: Springer, **2012**.
16. R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing, **2013**.
17. Lloyd-Smith JO. Maximum likelihood estimation of the negative binomial dispersion parameter for highly overdispersed data, with applications to infectious diseases. *PLoS One* **2007**; 2(2): e180.
18. Venables WN, Ripley BD. *Modern Applied Statistics with S*. Fourth ed. New York: Springer, **2002**.
19. Arena F, Giani T, Becucci E, et al. Large oligoclonal outbreak due to *Klebsiella pneumoniae* ST14 and ST26 producing the FOX-7 AmpC beta-

- lactamase in a neonatal intensive care unit. J Clin Microbiol **2013**; 51(12): 4067-72.
20. Giani T, Arena F, Vaggelli G, et al. Large Nosocomial Outbreak of Colistin-Resistant, Carbapenemase-Producing *Klebsiella pneumoniae* Traced to Clonal Expansion of an *mgrB* Deletion Mutant. J Clin Microbiol **2015**; 53(10): 3341-4.
 21. Pitout JD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing *Escherichia coli* strains in the Calgary health region. J Clin Microbiol **2005**; 43(6): 2844-9.
 22. Kassis-Chikhani N, Decre D, Gautier V, et al. First outbreak of multidrug-resistant *Klebsiella pneumoniae* carrying *blaVIM-1* and *blaSHV-5* in a French university hospital. J Antimicrob Chemother **2006**; 57(1): 142-5.
 23. Carrer A, Lassel L, Fortineau N, et al. Outbreak of CTX-M-15-producing *Klebsiella pneumoniae* in the intensive care unit of a French hospital. Microb Drug Resist **2009**; 15(1): 47-54.
 24. Garcia-Fernandez A, Villa L, Carta C, et al. *Klebsiella pneumoniae* ST258 producing KPC-3 identified in Italy carries novel plasmids and OmpK36/OmpK35 porin variants. Antimicrob Agents Chemother **2012**; 56(4): 2143-5.